The Value of 3CL Protease Inhibitor Supplementation in Long Haul Syndrome Patients?
Citation: D. Arad, A. Blumenthal, E. Brownell, Z. Tasnim, M. March-Steinman, Y. Jones, C. Herrold, The Value of 3CL Protease Inhibitor Supplementation in Long Haul Syndrome Patients?, ResearchGate (not peer-reviewed), 2022/08/19, 10.13140/RG.2.2.18668.44162
Key Tollovid Data: Here, through a series of 104 case study respondents in an IRB-waived market research self-reported questionnaire, we highlight emerging evidence concerning positive clinical and immunological impacts of supplementation with Tollovid, a natural, botanically-based immune cleanse/support dietary supplement with potent 3CL protease inhibitory activity in vitro, first reported here, in patients suffering from Acute COVID and LHS-related symptoms.